Cugene Receives FDA Approval for Phase 1a Healthy Volunteer Study of CUG252, a Treg-Selective Long-Acting IL-2

Cugene is launching its first-in-human study for subcutaneously administered CUG252 in healthy volunteers, evaluating its safety, tolerability, pharmacokinetics and pharmacodynamics.

The release as fetched from its publisher. cugene.com ↗